Humacyte to Present at the Piper Sandler 36th Annual Healthcare Conference
Humacyte to Present at the Piper Sandler 36th Annual Healthcare Conference
DURHAM, N.C., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Founder, President, and Chief Executive Officer, will participate in a fireside chat presentation at the Piper Sandler 36th Annual Healthcare Conference, in New York, NY on Thursday, December 5, 2024. Management will also be available for one-on-one meetings.
2024年12月02日，北卡羅來納州杜罕（DURHAm）（環球新聞社）——生物技術平台公司Humacyte, Inc.（納斯達克股票代碼：HUMA）是一家臨床階段公司，致力於開發可廣泛植入的人體工程化組織，並實現商業化規模。該公司今天宣佈，創始人、總裁兼首席執行官Laura Niklason博士將於2024年12月5日星期四在紐約舉行的派傑投資第36屆醫療保健年會上參加一場對話活動。管理層還將提供一對一會議。
Event: Piper Sandler 36th Annual Healthcare Conference
Location: The Lotte New York Palace, NY
Presentation: Thursday, December 5, 8:00 a.m. EST
Webcast:
事件：派傑投資第36屆年度醫療大會
地點：紐約Lotte New York Palace酒店
演講時間：2024年12月5日，美東時間上午8:00
網絡直播：
A replay will be available for a limited time following the presentation on the Events & Presentations portion of the Humacyte website.
演講結束後，Humacyte網站的「事件與演示文稿」部分將提供一段有限時間的回放。
About Humacyte
關於Humacyte
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. Humacyte develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Humacyte's initial product candidates, a portfolio of ATEVs, are currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous (AV) access for hemodialysis, and peripheral artery disease. A Biologics License Application for the ATEV in the vascular trauma indication is currently under review by the FDA and was granted Priority Review. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte's 6mm ATEV for AV access in hemodialysis was the first product candidate to receive the FDA's Regenerative Medicine Advanced Therapy (RMAT) designation and has also received FDA Fast Track designation. Humacyte's 6mm ATEV for urgent arterial repair following extremity vascular trauma and for advanced PAD also have received an RMAT designations. The ATEV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit .
Humacyte, Inc. (納斯達克：HUMA) 正在開發一種顛覆性的生物技術平台，用於提供可普遍植入的生物工程人類組織、先進組織結構和器官系統，旨在改善患者生活並改變醫學實踐。Humacyte 開發並製造無細胞組織，用於治療廣泛的疾病、損傷和慢性病。Humacyte 的最初產品候選品，一系列ATEV，目前處於針對多種血管應用的晚期臨床試驗階段，包括血管創傷修復、血管通路透析和周圍動脈疾病。ATEV 在血管創傷適應症方面的生物治療許可申請目前正在接受FDA審查，並獲得了優先審查。其臨床前開發還在冠狀動脈搭橋移植、小兒心臟手術、治療1型糖尿病以及多種新型細胞和組織應用方面進行。Humacyte 的用於血管通路透析的6mmATEV是首個獲得FDA再生醫學先進療法（RMAT）指定的產品候選品，也獲得了FDA快速通道指定。用於急性肢體血管創傷後緊急動脈修復以及進展性PAD的6mmATEV也已獲得RMAT指定。該ATEV被美國國防部長優先指定爲治療血管創傷。有關更多信息，請訪問。
Humacyte Investor Contact:
Joyce Allaire
LifeSci Advisors LLC
+1-617-435-6602
jallaire@lifesciadvisors.com
investors@humacyte.com
Humacyte投資者聯繫方式：
喬伊斯·阿萊爾
LifeSci Advisors LLC
+1-617-435-6602
jallaire@lifesciadvisors.com
investors@humacyte.com
Humacyte Media Contact:
Rich Luchette
Precision Strategies
+1-202-845-3924
rich@precisionstrategies.com
media@humacyte.com
Humacyte媒體聯繫人：
Rich Luchette
Precision Strategies
+1-202-845-3924
rich@precisionstrategies.com
media@humacyte.com
譯文內容由第三人軟體翻譯。